Prevalence of antibodies against seasonal influenza a and b viruses during the 2009-2010 and 2010-2011 influenza seasons in residents of Pittsburgh, PA, USA

PLoS Currents

Volumn , Issue , 2011, Pages

  Ross, Ted M ^a   hairong, Lu ^a   Chia, Bing Shao ^a   Hill, Elaise ^a   Weirback, Heather ^a   Zimmer, Shanta ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA A ANTIBODY; INFLUENZA B ANTIBODY; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; ANTIBODY;

2009 H1N1 INFLUENZA; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; HEMAGGLUTINATION INHIBITION; INFLUENZA A; INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; SAMPLE SIZE; SEASONAL INFLUENZA; SEROPREVALENCE; UNITED STATES; ADOLESCENT; ADULT; AGED; CHILD; CONTROLLED STUDY; GEOGRAPHIC DISTRIBUTION; HEMAGGLUTINATION; HUMAN; INFANT; INFLUENZA VIRUS A H1N1; VIRUS STRAIN;

EID: 84867448286     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1265     Document Type: Article

References (24)

1. Longini IM, Jr., Koopman JS, Monto AS, Fox JP (1982) Estimating household and community transmission parameters for influenza. Am J Epidemiol 115: 736-751.
2. Lowen AC, Mubareka S, Steel J, Palese P (2007) Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog 3: 1470-1476.
3. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186.
4. Bodewes R, Kreijtz JH, Baas C, Geelhoed-Mieras MM, de Mutsert G, et al. (2009) Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS One 4: e5538.
5. Guo H, Santiago F, Lambert K, Takimoto T, Topham DJ (2011) T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. J Virol 85: 448-455.
6. Seo SH, Peiris M, Webster RG (2002) Protective cross-reactive cellular immunity to lethal A/Goose/Guangdong/1/96-like H5N1 influenza virus is correlated with the proportion of pulmonary CD8(+) T cells expressing gamma interferon. J Virol 76: 4886-4890.
7. Zimmer S, Crevar C, Carter D, Stark J, Giles B, et al. (2010) Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza in Pittsburgh, PA, USA. PLOS One 5: e11601.
8. Adamson WE, McGregor EC, Kavanagh K, McMenamin J, McDonagh S, et al. (2011) Influenza A(H1N1)2009 antibody seroprevalence in Scotland following the 2010/11 influenza season. Euro Surveill 16: 19871.
9. Allwinn R, Geiler J, Berger A, Cinatl J, Doerr HW (2010) Determination of serum antibodies against swineorigin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans? Med Microbiol Immunol 199: 117-121.
10. CDC (2009) Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 58: 433-435.
11. http://www.cdc.gov/vaccines/recs/acip/default.htm (2011) ACIP Provisional Recommendations Altanta: CDC.
12. Bandaranayake D, Huang QS, Bissielo A, Wood T, Mackereth G, et al. (2010) Risk factors and immunity in a nationally representative population following the 2009 influenza A(H1N1) pandemic. PLoS One 5: e13211.
13. Chen MI, Lee VJ, Lim WY, Barr IG, Lin RT, et al. (2010) 2009 influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore. JAMA 303: 1383-1391.
14. Cowling BJ, Chan KH, Fang VJ, Lau LL, So HC, et al. (2010) Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 362: 2175-2184.
15. Gilbert GL, Cretikos MA, Hueston L, Doukas G, O'Toole B, et al. (2010) Influenza A (H1N1) 2009 antibodies in residents of New South Wales, Australia, after the first pandemic wave in the 2009 southern hemisphere winter. PLoS One 5: e12562.
16. McVernon J, Laurie K, Nolan T, Owen R, Irving D, et al. (2010) Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October - December 2009. Euro Surveill 15.
17. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, et al. (2010) Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 375: 1100-1108.
18. Waalen K, Kilander A, Dudman SG, Krogh GH, Aune T, et al. (2010) High prevalence of antibodies to the 2009 pandemic influenza A(H1N1) virus in the Norwegian population following a major epidemic and a large vaccination campaign in autumn 2009. Euro Surveill 15.
19. Wu JT, Ma ES, Lee CK, Chu DK, Ho PL, et al. (2010) The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis 51: 1184-1191.
20. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, et al. (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361: 1945-1952.
21. Hardelid P, Andrews NJ, Hoschler K, Stanford E, Baguelin M, et al. (2010) Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009. Health Technol Assess 14: 115-192.
22. Huang DT, Shao PL, Huang KC, Lu CY, Wang JR, et al. (2011) Serologic status for pandemic (H1N1) 2009 virus, Taiwan. Emerg Infect Dis 17: 76-78.
23. Ikonen N, Strengell M, Kinnunen L, Osterlund P, Pirhonen J, et al. (2010) High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill 15.
24. Rizzo C, Rota MC, Bella A, Alfonsi V, Declich S, et al. (2010) Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period. Vaccine 28: 3558-3562.